Boston, Ma., USA – Intarcia Therapeutics, Inc., a pharmaceutical company, announced the hiring of Eddie Li to the newly created position of vice president and global head of regulatory affairs.[break]
Dr. Li brings more than 20 years of experience in regulatory affairs to Intarcia and he will be a member of the Executive team. Prior to joining Intarcia, Dr. Li served as Vice President and Head of U.S. Regulatory Affairs at Novo Nordisk, where he was also a member of the Leadership Team of the U.S. Clinical, Medical, Regulatory and Safety Organization. Dr. Li led and managed all regulatory functions across therapeutic areas including diabetes, obesity, hemophilia, and inflammation.
Prior to Novo Nordisk, Dr. Li worked with Sanofi, where he served in a variety of product/therapeutic team leadership and senior strategic advisory roles within Global Regulatory Affairs.
He also held the positions of Director and Head of Regulatory Development at Johnson & Johnson/McNeil Consumer & Specialty Pharmaceuticals, Senior Manager, Worldwide Regulatory Affairs at AstraZeneca, and Senior Toxicologist at Warner - July 18, 2013, Boston, Ma., USA – Intarcia Therapeutics, Inc., a pharmaceutical company, announced the hiring of Eddie Li to the newly created position of vice president and global head of regulatory affairs.
Article continues below
]
Dr. Li brings more than 20 years of experience in regulatory affairs to Intarcia and he will be a member of the Executive team. Prior to joining Intarcia, Dr. Li served as Vice President and Head of U.S. Regulatory Affairs at Novo Nordisk, where he was also a member of the Leadership Team of the U.S. Clinical, Medical, Regulatory and Safety Organization. Dr. Li led and managed all regulatory functions across therapeutic areas including diabetes, obesity, hemophilia, and inflammation.
Prior to Novo Nordisk, Dr. Li worked with Sanofi, where he served in a variety of product/therapeutic team leadership and senior strategic advisory roles within Global Regulatory Affairs.
He also held the positions of Director and Head of Regulatory Development at Johnson & Johnson/McNeil Consumer & Specialty Pharmaceuticals, Senior Manager, Worldwide Regulatory Affairs at AstraZeneca, and Senior Toxicologist at Warner-Lambert/Parke-Davis Pharmaceuticals. Dr. Li also worked as a staff reviewer at the U.S. FDA’s Center for Drug Evaluation and Research (CDER) in the Division of Neuropharmacological Drug Products. ■